Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

Allergan71 enrolled

Overview

The purpose of this PMS study is to evaluate the safety and effectiveness of BELKYRA Inj. used according to the dose specified in the instructions for use, for the treatment of patients with SM fullness due to SMF, through active investigation under routine clinical practice

Study Type

OBSERVATIONAL

Enrollment

Conditions

Submental Fullness

Interventions

BELKYRA Inj.DRUG

Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Eligible and consenting Korean patients * Patients who have consented to the study and who have signed the private information protection act form or ICF Exclusion Criteria: * Patients having infection at the infection sites * Patients presenting evidence of causes of enlarged submental area other than localized submental fat (E.g.: thyroid enlargement, enlarged submental salivary glands, cervical lymphadenopathy, etc.) * Patients participating in an interventional clinical study, currently or within 30 days before enrollment, will not be eligible for inclusion in the study * Pregnant women * Renal impairment patients * Hepatic impairment patients * Patients with severe laxity

Locations (4)

Oracle-Dermatology

Daejeon, South Korea

Goldenview plastic surgery

Seoul, South Korea

(Apgujeong) Oracle-Dermatology

Seoul, South Korea

Dream-Dermatology

Seoul, South Korea

Outcomes

Primary Outcomes

Change from baseline in Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)

A validated scale used by investigators to assess SM convexity/amount of SMF. Specifically, the CR-SMFRS ranges in whole number increments from 0 (absent submental convexity) to 4 (extreme submental convexity)

Time frame: Baseline, Follow up visit (within 3 months of injection)

Change from baseline in Patient-Reported Submental Fat Rating Scale (PR-SMFRS)

Validated scale used by patients to evaluate SM size. Specifically, the PR-SMFRS asks patients to assess how much fat they have under their chins by selecting options ranging from "no chin fat at all" to "a very large amount of chin fat".

Time frame: Baseline, Follow up visit (within 3 months of injection)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.